Clicky

TScan Therapeutics, Inc.(TCRX)

Description: TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, focuses on developing a pipeline of T cell receptor-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation; and TSC-200, TSC-201, TSC-202, and TSC-203 for the treatment of solid tumors. The company has a collaboration and license agreement with Novartis Institutes for Biomedical Research, Inc. to discover and develop novel TCR-T therapies. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.


Keywords: Cancer Life Sciences Immunology Health Care Solid Tumors Immune System Transplantation Hematologic Malignancies T Cell Tumors Of The Hematopoietic And Lymphoid Tissues Preclinical Stage Biopharmaceutical Therapies For The Treatment Of Patients With Cancer

Home Page: www.tscan.com

TCRX Technical Analysis

830 Winter Street
Waltham, MA 02451
United States
Phone: 857 399 9500


Officers

Name Title
Mr. David P. Southwell Pres, CEO & Director
Mr. Brian Michael Silver J.D. Sr. VP, CFO & Treasurer
Dr. Gavin MacBeath Ph.D. Chief Scientific & Operations Officer
Dr. Stephen J. Elledge Ph.D. Co-Founder & Chairman of Scientific Advisory Board
Mr. Tomasz Kula Ph.D. Co-Founder & Member of Advisory Board
Mr. Ray Lockard VP of Technical Operations & Quality
Ms. Heather Savelle VP of Investor Relations
Dr. Zoran Zdraveski J.D., Ph.D. Chief Legal Officer & Company Sec.
Ms. Ann Hargraves VP of HR
Dr. William Desmarais M.B.A., Ph.D. Chief Bus. Officer

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 0.4211
Price-to-Sales TTM: 3.4415
IPO Date: 2021-07-16
Fiscal Year End: December
Full Time Employees: 127
Back to stocks